How Sol-Gel is Responding to Covid-19

TWYNEO® Treatment for Acne Vulgaris is now FDA APPROVED

Novel Delivery Technology Designed to Control Topical Drug Release

Research is currently being conducted using our proprietary silica-based delivery technology, which utilizes a microencapsulation process, to determine if it improves the tolerability of topical dermatological drug products. The topical delivery technology is designed to control the release profile of drug substances.

New Drug Combinations

New Drug Combinations

Research using our proprietary silica-based delivery technology platform is also ongoing to determine if two otherwise incompatible drug substances can be combined in the same formulation.

Our Product Pipeline

Sol-Gel is developing a diverse pipeline of innovative topical skin medications, some based on our propriety silica-based delivery technology.

View Our Pipeline